Point Therapeutics - 500 Beiträge pro Seite
eröffnet am 12.01.07 15:25:11 von
neuester Beitrag 09.06.07 18:39:24 von
neuester Beitrag 09.06.07 18:39:24 von
Beiträge: 25
ID: 1.104.855
ID: 1.104.855
Aufrufe heute: 0
Gesamt: 2.788
Gesamt: 2.788
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| 26.04.24, 14:53 | 660 | |
| gestern 23:32 | 224 | |
| vor 1 Stunde | 199 | |
| heute 00:14 | 176 | |
| gestern 22:06 | 167 | |
| gestern 18:36 | 161 | |
| heute 00:33 | 156 | |
| gestern 16:03 | 100 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.159,50 | -0,16 | 207 | |||
| 2. | 2. | 194,05 | +15,31 | 119 | |||
| 3. | 3. | 2.329,58 | -0,22 | 59 | |||
| 4. | 4. | 65,95 | -2,66 | 50 | |||
| 5. | 5. | 7,9000 | +7,48 | 46 | |||
| 6. | 6. | 0,8300 | -29,66 | 39 | |||
| 7. | 7. | 15,116 | -5,73 | 38 | |||
| 8. | 8. | 0,1785 | -7,03 | 30 |
Feedback
POTP (1.15) Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Business Wire "US Press Releases "
BOSTON--(BUSINESS WIRE)--
Point Therapeutics, Inc. (NASDAQ: POTP) today provided preliminary results from the Company's open-label Phase 2 trial of talabostat plus gemcitabine in patients with metastatic pancreatic cancer (Stage IV) who have not received prior chemotherapy.
Of the 21 evaluable patients who entered the study at least six months ago, ten (48%) have survived more than six months. In addition, 31 patients are currently evaluable for tumor response. To date, three patients (9.7%) have demonstrated a clinical response to treatment, including one complete response and two partial responses. One patient with metastatic disease to the liver experienced a complete response to treatment--defined as the complete disappearance of tumor. Thus far, no unexpected toxicities have been seen in the trial that would prevent the Company from continuing to study talabostat in combination with gemcitabine.
The Phase 2 study is a single-arm, two-stage study in up to 60 evaluable patients with metastatic pancreatic cancer. The primary clinical endpoint is six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status. The Phase 2 study protocol called for an interim assessment before advancing the study to completion. Based on the preliminary six-month survival results and the responses seen to date, the Company has decided to advance the study to completion. Final results from the study are expected mid-year 2007.
"Metastatic pancreatic cancer represents a significant unmet medical need as there are limited treatment options available for patients. I am pleased with the activity seen to date in this trial, especially with an oral agent, and look forward to evaluating further data as it becomes available," said Dr. Yagnesh Oza, MD, Medical Director at the Center for Comprehensive Cancer Care in Mt. Vernon, IL and an investigator in the study.
"It's encouraging to see Point's preclinical work potentially translating into clinical benefits for patients," said Dr. George Demetri, a member of Point's Clinical Advisory Board and Director of the Ludwig Center at Dana-Farber/Harvard. "Point has demonstrated preclinically that talabostat is a potent inhibitor of fibroblast activation protein (FAP), an enzyme that is highly expressed in pancreatic cancer and is believed to promote tumor growth. In addition, preclinical work combining talabostat with gemcitabine has also demonstrated encouraging results. I believe these factors make pancreatic cancer a promising target for the study of talabostat," concluded Dr. Demetri.
About Pancreatic Cancer:
According to the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2006 alone, 33,730 new cases of pancreatic cancer were diagnosed and 32,300 people died of the disease. The main reason for the poor prognosis of pancreatic cancer is that patients usually have no symptoms until the cancer has spread to other organs, and, as a result, very few of these cancers are found early. Patients with Stage IV disease have the most advanced form of pancreatic cancer, which includes metastatic disease to distant organ(s).
About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company which is currently studying its lead product candidate, talabostat, in two Phase 3 double blind placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.
Certain statements contained herein are not strictly historical and are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements with respect to the company's clinical development programs and the timing of initiation and completion of its clinical trials. Forward-looking statements are statements that are not historical facts, and can be identified by, among other things, the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "projects," "should," "seeks," "plans," "schedules to," "anticipates" or "intends" or the negative of those terms, or other variations of those terms of comparable language, or by discussions of strategy or intentions. A number of important factors could cause actual results to differ materially from those projected or suggested in the forward looking statement, including the risk factors described in Point's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006, and from time to time in Point's other reports filed with the Securities and Exchange Commission.
Source: Point Therapeutics, Inc.
Business Wire "US Press Releases "
BOSTON--(BUSINESS WIRE)--
Point Therapeutics, Inc. (NASDAQ: POTP) today provided preliminary results from the Company's open-label Phase 2 trial of talabostat plus gemcitabine in patients with metastatic pancreatic cancer (Stage IV) who have not received prior chemotherapy.
Of the 21 evaluable patients who entered the study at least six months ago, ten (48%) have survived more than six months. In addition, 31 patients are currently evaluable for tumor response. To date, three patients (9.7%) have demonstrated a clinical response to treatment, including one complete response and two partial responses. One patient with metastatic disease to the liver experienced a complete response to treatment--defined as the complete disappearance of tumor. Thus far, no unexpected toxicities have been seen in the trial that would prevent the Company from continuing to study talabostat in combination with gemcitabine.
The Phase 2 study is a single-arm, two-stage study in up to 60 evaluable patients with metastatic pancreatic cancer. The primary clinical endpoint is six-month survival. Secondary study endpoints include overall survival, progression-free survival, quality of life, and performance status. The Phase 2 study protocol called for an interim assessment before advancing the study to completion. Based on the preliminary six-month survival results and the responses seen to date, the Company has decided to advance the study to completion. Final results from the study are expected mid-year 2007.
"Metastatic pancreatic cancer represents a significant unmet medical need as there are limited treatment options available for patients. I am pleased with the activity seen to date in this trial, especially with an oral agent, and look forward to evaluating further data as it becomes available," said Dr. Yagnesh Oza, MD, Medical Director at the Center for Comprehensive Cancer Care in Mt. Vernon, IL and an investigator in the study.
"It's encouraging to see Point's preclinical work potentially translating into clinical benefits for patients," said Dr. George Demetri, a member of Point's Clinical Advisory Board and Director of the Ludwig Center at Dana-Farber/Harvard. "Point has demonstrated preclinically that talabostat is a potent inhibitor of fibroblast activation protein (FAP), an enzyme that is highly expressed in pancreatic cancer and is believed to promote tumor growth. In addition, preclinical work combining talabostat with gemcitabine has also demonstrated encouraging results. I believe these factors make pancreatic cancer a promising target for the study of talabostat," concluded Dr. Demetri.
About Pancreatic Cancer:
According to the American Cancer Society, pancreatic cancer is the fourth leading cause of cancer death in the United States. In 2006 alone, 33,730 new cases of pancreatic cancer were diagnosed and 32,300 people died of the disease. The main reason for the poor prognosis of pancreatic cancer is that patients usually have no symptoms until the cancer has spread to other organs, and, as a result, very few of these cancers are found early. Patients with Stage IV disease have the most advanced form of pancreatic cancer, which includes metastatic disease to distant organ(s).
About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company which is currently studying its lead product candidate, talabostat, in two Phase 3 double blind placebo-controlled trials in non-small cell lung cancer and in a Phase 2 trial in combination with gemcitabine in metastatic pancreatic cancer. Point has also studied talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma and in combination with rituximab in advanced chronic lymphocytic leukemia.
Certain statements contained herein are not strictly historical and are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements with respect to the company's clinical development programs and the timing of initiation and completion of its clinical trials. Forward-looking statements are statements that are not historical facts, and can be identified by, among other things, the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "projects," "should," "seeks," "plans," "schedules to," "anticipates" or "intends" or the negative of those terms, or other variations of those terms of comparable language, or by discussions of strategy or intentions. A number of important factors could cause actual results to differ materially from those projected or suggested in the forward looking statement, including the risk factors described in Point's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2006, and from time to time in Point's other reports filed with the Securities and Exchange Commission.
Source: Point Therapeutics, Inc.
RT USA 1,22
+ 43,53 %
+ 43,53 %
RT 1,27
Trading Spotlight
Bin schon seit Dezember letzten Jahres investiert.
Die MK von ca. 38 Mio Dollar ist im Verhältnis zur Pipeline relativ günstig:
Gruß Cyberhai
Die MK von ca. 38 Mio Dollar ist im Verhältnis zur Pipeline relativ günstig:
Gruß Cyberhai
hält sich aber gut im plus
Antwort auf Beitrag Nr.: 26.863.787 von axcol am 12.01.07 16:50:57Hmmm, hab noch ne Order für 1 US $ drin. Sieht aber nicht so aus das ich heute bedient werde...
Punkt-Therapeutik liefert Einleitung-Resultate Phase 2 Metastatic von der pankreatischen Krebs-Studie
Firma-Fortschritte studieren zur Beendigung
BOSTON--(GESCHÄFT LEITUNG)--12. Jan. 2007--Point Therapeutics, Inc. (Nasdaq: POTP) versah heute Einleitungresultate vom open-label Phase 2 der Firma Versuch von talabostat plus gemcitabine bei Patienten mit metastatic pankreatischem Krebs (Stadium IV) die nicht vorherige Chemotherapie empfangen haben.
Eintrugen vor, von den 21 evaluable Patienten, die die Studie mindestens sechs Monaten, haben 10 (48%) mehr als sechs Monate überlebt. Zusätzlich sind 31 Patienten z.Z. für Tumorantwort evaluable. Bis jetzt haben drei Patienten (9.7%) eine klinische Antwort zur Behandlung, einschließlich eine komplette Antwort und zwei teilweise Antworten demonstriert. Ein Patient mit metastatic Krankheit zur Leber erfuhr eine komplette Antwort zur Behandlung--definiert als das komplette Verschwinden des Tumors. Bis jetzt ist keine unerwartete Giftigkeit in den Versuch gesehen worden, der die Firma am Fortfahren, talabostat im Verbindung mit gemcitabine zu studieren verhindern würde.
Die Phase 2 Studie ist ein Einzelnarm, zweistufige Studie bei bis 60 evaluable Patienten mit metastatic pankreatischem Krebs. Der klinische hauptsächlichendpunkt ist Sechsmonatsüberleben. Sekundärstudie Endpunkte schließen gesamtes überleben, Weiterentwicklung-freies überleben, Lebensqualität und Leistung Status ein. Das Phase 2 Studie Protokoll verlangte eine Zwischenzeitseinschätzung, bevor es die Studie zur Beendigung vorrückte. Gegründet auf den einleitenden Sechsmonatsüberleben Resultaten und den Antworten, die bis jetzt gesehen werden, hat die Firma entschieden, die Studie zur Beendigung vorzurücken. Endrunde Resultate von der Studie werden Jahresmitte 2007 erwartet.
„Metastatic pankreatischer Krebs stellt eine bedeutendes unmet medizinische Notwendigkeit dar, da es die begrenzten Behandlungwahlen gibt, die für Patienten vorhanden sind. Ich werde mit der Tätigkeit gefallen, die bis jetzt in diesen Versuch, besonders mit einem Mundmittel gesehen werden, und Blick vorwärts zu auswertenden weiteren Daten, während er vorhanden wird,“ sagte Dr. Yagnesh Oza, MD, medizinischer Direktor in der Mitte für komplette Krebs-Obacht in Millitorr Vernon, IL und ein Forscher in der Studie.
„Sie regt an, um preclinical Arbeit des Punktes in, klinischen Nutzen möglicherweise zu übersetzen für Patienten zu sehen,“, sagte Dr. George Demetri, ein Mitglied der klinischen Beratungsstelle des Punktes und Direktor der Ludwig Mitte in Dana-Farber/in Harvard. „Punkt hat preclinically, daß talabostat ein starkes Hemmnis des Fibroblastaktivierung Proteins (FAP) ist, ein Enzym gezeigt, das in hohem Grade im pankreatischen Krebs ausgedrückt wird und geglaubt wird, um Tumorwachstum zu fördern. Zusätzlich hat die preclinical Arbeit, die talabostat mit gemcitabine kombiniert, auch anregenresultate gezeigt. Ich glaube, daß diese Faktoren pankreatischen Krebs ein vielversprechendes Ziel für die Studie des talabostat,“ gefolgerter Dr. Demetri bilden.
Über pankreatischen Krebs:
Nach Ansicht der amerikanischen Krebs-Gesellschaft ist pankreatischer Krebs die vierte führende Ursache des Krebstodes in den Vereinigten Staaten. In 2006 allein wurden 33.730 neue Kästen pankreatischer Krebs bestimmt und 32.300 Leute gestorben an der Krankheit. Der Hauptgrund für die schlechte Prognose des pankreatischen Krebses ist, daß Patienten normalerweise keine Symptome haben, bis der Krebs zu anderen Organen verbreitet hat, und infolgedessen sehr werden wenige dieser Krebse früh gefunden. Patienten mit Stadium IV Krankheit haben die vorgerückteste Form des pankreatischen Krebses, der metastatic Krankheit zu den entfernten Organen einschließt.
Über Point Therapeutics, Inc.:
Punkt ist eine Boston-gegründete biopharmaceutical Firma, die z.Z. seinen Leitung Produktanwärter, talabostat, in den Zweiphasen3 doppelten blinden Placebo-kontrollierten Versuchen im nicht-kleinen Zelle Lungenkrebs und in einem Phase 2 Versuch im Verbindung mit gemcitabine im metastatic pankreatischen Krebs studiert. Punkt hat auch talabostat in mehreren Phase 2 die Versuche studiert und geschlossen als Einzelnmittel im metastatic Melanomen, im Verbindung mit cisplatin im metastatic Melanomen und im Verbindung mit rituximab in vorgerückter chronischer lymphozytischer Leukämie ein.
Bestimmte Aussagen, die hierin enthalten werden, sind nicht ausschließlich historisch und sind „schauende“ Vorwärtsaussagen, wie in der privaten Sicherheiten Rechtsstreit-Verbesserung-Tat von 1995 definiert. Diese Aussagen schließen, ohne Beschränkung, Aussagen in Bezug auf die klinischen Entwicklungsprogramme der Firma und das TIMING der Einführung und Beendigung seiner klinischen Versuche ein. Vorwärts-schauend sind Aussagen Aussagen, die nicht historische Tatsachen sind, und können vorbei gekennzeichnet werden unter anderem der Gebrauch von Vorwärts-Schauen von Sprache, wie „glaubt,“ „glaubt,“ „erwartet,“ „können,“ „werden,“ „Projekte,“ „,“ „Suchvorgänge,“ „Pläne,“ „legt zu fest,“ „nimmt“ vorweg, oder „beabsichtigt“ oder das Negativ jener Bezeichnungen oder andere Veränderungen jener Bezeichnungen der vergleichbaren Sprache oder durch Diskussionen über Strategie oder Absichten. Eine Anzahl von den wichtigen Faktoren konnte tatsächliche Resultate veranlassen, sich von denen materiell zu unterscheiden projiziert oder in der schauenden Vorwärtsaussage, einschließlich die Gefahr Faktoren vorgeschlagen, die im vierteljährlichen Report des Punktes auf der Form 10-Q beschrieben wurden, eingeordnet mit der Sicherheiten und Austausch-Kommission am 9. November 2006 und gelegentlich in anderen Reports des Punktes, die mit der Sicherheiten und Austausch-Kommission vorgelegt wurden.
KONTAKT: Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Direktor, Unternehmenskommunikationen
QUELLE: Point Therapeutics, Inc.
Firma-Fortschritte studieren zur Beendigung
BOSTON--(GESCHÄFT LEITUNG)--12. Jan. 2007--Point Therapeutics, Inc. (Nasdaq: POTP) versah heute Einleitungresultate vom open-label Phase 2 der Firma Versuch von talabostat plus gemcitabine bei Patienten mit metastatic pankreatischem Krebs (Stadium IV) die nicht vorherige Chemotherapie empfangen haben.
Eintrugen vor, von den 21 evaluable Patienten, die die Studie mindestens sechs Monaten, haben 10 (48%) mehr als sechs Monate überlebt. Zusätzlich sind 31 Patienten z.Z. für Tumorantwort evaluable. Bis jetzt haben drei Patienten (9.7%) eine klinische Antwort zur Behandlung, einschließlich eine komplette Antwort und zwei teilweise Antworten demonstriert. Ein Patient mit metastatic Krankheit zur Leber erfuhr eine komplette Antwort zur Behandlung--definiert als das komplette Verschwinden des Tumors. Bis jetzt ist keine unerwartete Giftigkeit in den Versuch gesehen worden, der die Firma am Fortfahren, talabostat im Verbindung mit gemcitabine zu studieren verhindern würde.
Die Phase 2 Studie ist ein Einzelnarm, zweistufige Studie bei bis 60 evaluable Patienten mit metastatic pankreatischem Krebs. Der klinische hauptsächlichendpunkt ist Sechsmonatsüberleben. Sekundärstudie Endpunkte schließen gesamtes überleben, Weiterentwicklung-freies überleben, Lebensqualität und Leistung Status ein. Das Phase 2 Studie Protokoll verlangte eine Zwischenzeitseinschätzung, bevor es die Studie zur Beendigung vorrückte. Gegründet auf den einleitenden Sechsmonatsüberleben Resultaten und den Antworten, die bis jetzt gesehen werden, hat die Firma entschieden, die Studie zur Beendigung vorzurücken. Endrunde Resultate von der Studie werden Jahresmitte 2007 erwartet.
„Metastatic pankreatischer Krebs stellt eine bedeutendes unmet medizinische Notwendigkeit dar, da es die begrenzten Behandlungwahlen gibt, die für Patienten vorhanden sind. Ich werde mit der Tätigkeit gefallen, die bis jetzt in diesen Versuch, besonders mit einem Mundmittel gesehen werden, und Blick vorwärts zu auswertenden weiteren Daten, während er vorhanden wird,“ sagte Dr. Yagnesh Oza, MD, medizinischer Direktor in der Mitte für komplette Krebs-Obacht in Millitorr Vernon, IL und ein Forscher in der Studie.
„Sie regt an, um preclinical Arbeit des Punktes in, klinischen Nutzen möglicherweise zu übersetzen für Patienten zu sehen,“, sagte Dr. George Demetri, ein Mitglied der klinischen Beratungsstelle des Punktes und Direktor der Ludwig Mitte in Dana-Farber/in Harvard. „Punkt hat preclinically, daß talabostat ein starkes Hemmnis des Fibroblastaktivierung Proteins (FAP) ist, ein Enzym gezeigt, das in hohem Grade im pankreatischen Krebs ausgedrückt wird und geglaubt wird, um Tumorwachstum zu fördern. Zusätzlich hat die preclinical Arbeit, die talabostat mit gemcitabine kombiniert, auch anregenresultate gezeigt. Ich glaube, daß diese Faktoren pankreatischen Krebs ein vielversprechendes Ziel für die Studie des talabostat,“ gefolgerter Dr. Demetri bilden.
Über pankreatischen Krebs:
Nach Ansicht der amerikanischen Krebs-Gesellschaft ist pankreatischer Krebs die vierte führende Ursache des Krebstodes in den Vereinigten Staaten. In 2006 allein wurden 33.730 neue Kästen pankreatischer Krebs bestimmt und 32.300 Leute gestorben an der Krankheit. Der Hauptgrund für die schlechte Prognose des pankreatischen Krebses ist, daß Patienten normalerweise keine Symptome haben, bis der Krebs zu anderen Organen verbreitet hat, und infolgedessen sehr werden wenige dieser Krebse früh gefunden. Patienten mit Stadium IV Krankheit haben die vorgerückteste Form des pankreatischen Krebses, der metastatic Krankheit zu den entfernten Organen einschließt.
Über Point Therapeutics, Inc.:
Punkt ist eine Boston-gegründete biopharmaceutical Firma, die z.Z. seinen Leitung Produktanwärter, talabostat, in den Zweiphasen3 doppelten blinden Placebo-kontrollierten Versuchen im nicht-kleinen Zelle Lungenkrebs und in einem Phase 2 Versuch im Verbindung mit gemcitabine im metastatic pankreatischen Krebs studiert. Punkt hat auch talabostat in mehreren Phase 2 die Versuche studiert und geschlossen als Einzelnmittel im metastatic Melanomen, im Verbindung mit cisplatin im metastatic Melanomen und im Verbindung mit rituximab in vorgerückter chronischer lymphozytischer Leukämie ein.
Bestimmte Aussagen, die hierin enthalten werden, sind nicht ausschließlich historisch und sind „schauende“ Vorwärtsaussagen, wie in der privaten Sicherheiten Rechtsstreit-Verbesserung-Tat von 1995 definiert. Diese Aussagen schließen, ohne Beschränkung, Aussagen in Bezug auf die klinischen Entwicklungsprogramme der Firma und das TIMING der Einführung und Beendigung seiner klinischen Versuche ein. Vorwärts-schauend sind Aussagen Aussagen, die nicht historische Tatsachen sind, und können vorbei gekennzeichnet werden unter anderem der Gebrauch von Vorwärts-Schauen von Sprache, wie „glaubt,“ „glaubt,“ „erwartet,“ „können,“ „werden,“ „Projekte,“ „,“ „Suchvorgänge,“ „Pläne,“ „legt zu fest,“ „nimmt“ vorweg, oder „beabsichtigt“ oder das Negativ jener Bezeichnungen oder andere Veränderungen jener Bezeichnungen der vergleichbaren Sprache oder durch Diskussionen über Strategie oder Absichten. Eine Anzahl von den wichtigen Faktoren konnte tatsächliche Resultate veranlassen, sich von denen materiell zu unterscheiden projiziert oder in der schauenden Vorwärtsaussage, einschließlich die Gefahr Faktoren vorgeschlagen, die im vierteljährlichen Report des Punktes auf der Form 10-Q beschrieben wurden, eingeordnet mit der Sicherheiten und Austausch-Kommission am 9. November 2006 und gelegentlich in anderen Reports des Punktes, die mit der Sicherheiten und Austausch-Kommission vorgelegt wurden.
KONTAKT: Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Direktor, Unternehmenskommunikationen
QUELLE: Point Therapeutics, Inc.
Da ich letzte Woche nicht zu 1 US$ zum Zuge gekommen bin, probiere ich es heute mi 0,91 US-Cent...
Recent Trades - Last 10
Time Ex Price Change Volume
09:16:20 Q 1.01 +0.05 100
09:14:19 Q 1.06 +0.10 1,000
09:11:57 Q 1.05 +0.09 100
09:11:25 Q 1.02 +0.06 1,900
09:11:25 Q 0.99 +0.03 100
09:08:40 Q 1.02 +0.06 100
09:08:01 Q 0.99 +0.03 149,900
09:08:01 Q 0.99 +0.03 100
09:07:57 Q 0.99 +0.03 149,900
09:07:57 Q 0.99 +0.03 100
Time Ex Price Change Volume
09:16:20 Q 1.01 +0.05 100
09:14:19 Q 1.06 +0.10 1,000
09:11:57 Q 1.05 +0.09 100
09:11:25 Q 1.02 +0.06 1,900
09:11:25 Q 0.99 +0.03 100
09:08:40 Q 1.02 +0.06 100
09:08:01 Q 0.99 +0.03 149,900
09:08:01 Q 0.99 +0.03 100
09:07:57 Q 0.99 +0.03 149,900
09:07:57 Q 0.99 +0.03 100
Biotech News: Trade Alert for Point Therapeutics Inc
1/18/2007
Jan 18, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Trade Alert for Point Therapeutics Inc (NASDAQ:POTP)
Point Therapeutics is making sure that your blood actually is thicker than water. The development stage company is focused on developing drugs for the treatment of cancers and diabetes. The company's lead candidate talabostat is in late-stage clinical trials for the treatment of various types of cancer, including non-small cell lung cancer, metastatic melanoma, and pancreatic cancer. In preclinical development are treatments for type 2 diabetes and vaccine adjuvants for cancer and infectious diseases.
Shares were up 9% after releasing preliminary results from a phase II study of its drug talabostat.
BellwetherReport.com is a leading online research firm for international investors looking to get an edge over their portfolio. Investors seeking the most up to date information on Point Therapeutics Inc are invited to sign up for a free complimentary subscription to www.bellwetherreport.com. No credit card needed!
I'm often asked how I go about researching biotech stocks. The first thing I say is that it requires a lot of hard work. The successful biotech investor is part financial whiz, part savvy Wall Street technician and, most important, part scientist/medical expert.
It's the latter task that many people find the most difficult. Biotech companies issue press releases all the time touting the potential of their experimental drugs, and the stocks move as a result.
But how do you separate the truth from the hype? What sort of questions should you be asking yourself when you evaluate these press releases? And where can you find the unbiased information you need? As Jim Cramer often says, wisely, investing requires homework. So let's dissect a biotech press release to illustrate how it should be done.
On Friday, Point Therapeutics released preliminary results from a phase II study of its drug talabostat in patients with advanced pancreatic cancer.
I don't know much about Point Therapeutics or talabostat, so let's get to work learning more. But remember, I'm only using this announcement to illustrate how to research biotech stocks; I'm not making any judgment on the merits of Point Therapeautics as an investment -- it's a tiny, small-cap stock that trades at around $1.
Here's how the company's press release began: "Point Therapeutics, Inc. today provided preliminary results from the Company's open-label Phase 2 trial of talabostat plus gemcitabine in patients with metastatic pancreatic cancer (Stage IV) who have not received prior chemotherapy." For starters, I always look at something like this with a skeptical eye. Companies are in the business of selling themselves to investors, so you want to be critical. In this case, you need to be even more cautious because these results are preliminary, which means they will change.
More information on Point Therapeutics Inc available in the members section of www.BellwetherReport.com.
To review research on Point Therapeutics Inc as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!! The Bellwether Report will continue to research the small cap markets to bring you exciting opportunities!! If you are interested in receiving more information on these small cap opportunities and other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.
Companies looking to advertise with Bellwether Report should email jlee@bellwetherreport.com with the subject line (Advertising).
Information has been gathered from sources such as www.Hoovers.com, www.yahoo.com, www.associatedpress.com, www.marketwire.com, www.businesswire.com and other public resources.
All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2007 M2 COMMUNICATIONS LTD
1/18/2007
Jan 18, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Trade Alert for Point Therapeutics Inc (NASDAQ:POTP)
Point Therapeutics is making sure that your blood actually is thicker than water. The development stage company is focused on developing drugs for the treatment of cancers and diabetes. The company's lead candidate talabostat is in late-stage clinical trials for the treatment of various types of cancer, including non-small cell lung cancer, metastatic melanoma, and pancreatic cancer. In preclinical development are treatments for type 2 diabetes and vaccine adjuvants for cancer and infectious diseases.
Shares were up 9% after releasing preliminary results from a phase II study of its drug talabostat.
BellwetherReport.com is a leading online research firm for international investors looking to get an edge over their portfolio. Investors seeking the most up to date information on Point Therapeutics Inc are invited to sign up for a free complimentary subscription to www.bellwetherreport.com. No credit card needed!
I'm often asked how I go about researching biotech stocks. The first thing I say is that it requires a lot of hard work. The successful biotech investor is part financial whiz, part savvy Wall Street technician and, most important, part scientist/medical expert.
It's the latter task that many people find the most difficult. Biotech companies issue press releases all the time touting the potential of their experimental drugs, and the stocks move as a result.
But how do you separate the truth from the hype? What sort of questions should you be asking yourself when you evaluate these press releases? And where can you find the unbiased information you need? As Jim Cramer often says, wisely, investing requires homework. So let's dissect a biotech press release to illustrate how it should be done.
On Friday, Point Therapeutics released preliminary results from a phase II study of its drug talabostat in patients with advanced pancreatic cancer.
I don't know much about Point Therapeutics or talabostat, so let's get to work learning more. But remember, I'm only using this announcement to illustrate how to research biotech stocks; I'm not making any judgment on the merits of Point Therapeautics as an investment -- it's a tiny, small-cap stock that trades at around $1.
Here's how the company's press release began: "Point Therapeutics, Inc. today provided preliminary results from the Company's open-label Phase 2 trial of talabostat plus gemcitabine in patients with metastatic pancreatic cancer (Stage IV) who have not received prior chemotherapy." For starters, I always look at something like this with a skeptical eye. Companies are in the business of selling themselves to investors, so you want to be critical. In this case, you need to be even more cautious because these results are preliminary, which means they will change.
More information on Point Therapeutics Inc available in the members section of www.BellwetherReport.com.
To review research on Point Therapeutics Inc as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!! The Bellwether Report will continue to research the small cap markets to bring you exciting opportunities!! If you are interested in receiving more information on these small cap opportunities and other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.
Companies looking to advertise with Bellwether Report should email jlee@bellwetherreport.com with the subject line (Advertising).
Information has been gathered from sources such as www.Hoovers.com, www.yahoo.com, www.associatedpress.com, www.marketwire.com, www.businesswire.com and other public resources.
All material herein was prepared by the Bellwetherreport.com, (Bellwether) based upon information believed to be reliable. The information contained herein is not guaranteed by Bellwether to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bellwether is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Bellwether may receive compensation in cash or shares from independent third parties or from the companies mentioned.
Bellwether's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value.
Bellwether will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bellwether undertakes no obligation to update such statements.
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
(C)1994-2007 M2 COMMUNICATIONS LTD
POINT THERAPEUTICS INC
Early Alerts Aggressive Trade Opportunity for Friday, January 19, 2007: RHGP Announces Multi-Million Dollar Order!
1/19/2007
The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.
WESTON, FL, Jan 19, 2007 (MARKET WIRE via COMTEX News Network) --
TheSUBWAY.com announces the following stocks to its Action List: Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), Capstone Turbine Corporation (NASDAQ: CPST), Point Therapeutics Inc (NASDAQ: POTP), North American Scientific, Inc. (NASDAQ: NASI).
Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), just announced a major RMB 19 million (US$ 2.4 million) order from Anhui Huayuan Pharmaceutical Co. Ltd, which is one of the oldest and best known pharmaceutical companies in China. Renhuang Pharmaceuticals received the RMB 19 million order at the medical products purchasing conference in Taihe Town, Fuyang City in the Anhui Province. The conference is ranked as one of the biggest in the industry in China.
Renhuang Pharmaceuticals is a leading bio-pharmaceutical company located in Harbin in the Heilongjiang Province in Northeast China. It is estimated that 70% of China's natural supply of Siberian Ginseng is currently controlled by the Company. Over 2000 sales agents are employed in seventy sales centers across twenty-four districts and cover over 50% of the greater China area and 80% of its population, including the most populous and developed Eastern China. The company also anticipates approval within six to nine months by State Food and Drug Administration ("SFDA") for up to five of its new Monoclonal Antibody Reagent Box series products.
Other stocks highlighted include Capstone Turbine Corporation (NASDAQ: CPST): Hot Stocks List, down 1% on 6 million shares, Point Therapeutics Inc (NASDAQ: POTP): Hot Stocks List, up 18% on 2 million shares, North American Scientific, Inc. (NASDAQ: NASI): Hot Stocks List, up 11% on 2 million shares.
"Interest rate hikes are intended to keep the economy from overheating, a condition that could lead to dangerous inflation pressures. But after a strong showing of a 5.6 percent annual growth rate in the first quarter, the economy slowed to just a 2.9 percent pace in the second, and cooled even more in the third. And analysts are expecting the economy to have shown only moderate growth in the last quarter of the year. So the new Fed Chairman, Ben Bernanke, seems to have some breathing room for now." More is available at: http://www.thesubway.com.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated forty thousand shares for RHGP. CRG has also purchased five thousand shares in the open market. CRG intends to sell its shares. CRG has sold approximately zero RHGP shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned within and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
Chuck Tamburello Phone: 954-217-8555 Fax: 954-217-1500
SOURCE: TheSUBWAY.com
Copyright 2007 Market Wire, All rights reserved.
Early Alerts Aggressive Trade Opportunity for Friday, January 19, 2007: RHGP Announces Multi-Million Dollar Order!
1/19/2007
The Following Is an Investment Opinion Being Issued by Peter Antipatis of Capital Research Group Inc.
WESTON, FL, Jan 19, 2007 (MARKET WIRE via COMTEX News Network) --
TheSUBWAY.com announces the following stocks to its Action List: Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), Capstone Turbine Corporation (NASDAQ: CPST), Point Therapeutics Inc (NASDAQ: POTP), North American Scientific, Inc. (NASDAQ: NASI).
Renhuang Pharmaceuticals, Inc. (OTCBB: RHGP), just announced a major RMB 19 million (US$ 2.4 million) order from Anhui Huayuan Pharmaceutical Co. Ltd, which is one of the oldest and best known pharmaceutical companies in China. Renhuang Pharmaceuticals received the RMB 19 million order at the medical products purchasing conference in Taihe Town, Fuyang City in the Anhui Province. The conference is ranked as one of the biggest in the industry in China.
Renhuang Pharmaceuticals is a leading bio-pharmaceutical company located in Harbin in the Heilongjiang Province in Northeast China. It is estimated that 70% of China's natural supply of Siberian Ginseng is currently controlled by the Company. Over 2000 sales agents are employed in seventy sales centers across twenty-four districts and cover over 50% of the greater China area and 80% of its population, including the most populous and developed Eastern China. The company also anticipates approval within six to nine months by State Food and Drug Administration ("SFDA") for up to five of its new Monoclonal Antibody Reagent Box series products.
Other stocks highlighted include Capstone Turbine Corporation (NASDAQ: CPST): Hot Stocks List, down 1% on 6 million shares, Point Therapeutics Inc (NASDAQ: POTP): Hot Stocks List, up 18% on 2 million shares, North American Scientific, Inc. (NASDAQ: NASI): Hot Stocks List, up 11% on 2 million shares.
"Interest rate hikes are intended to keep the economy from overheating, a condition that could lead to dangerous inflation pressures. But after a strong showing of a 5.6 percent annual growth rate in the first quarter, the economy slowed to just a 2.9 percent pace in the second, and cooled even more in the third. And analysts are expecting the economy to have shown only moderate growth in the last quarter of the year. So the new Fed Chairman, Ben Bernanke, seems to have some breathing room for now." More is available at: http://www.thesubway.com.
TheSUBWAY.com's Daily Stock Updates:
TheSUBWAY.com, a leader in corporate communications and finance, highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions. The aforementioned commentary is not meant to be indicative of a "long term" view of any of the companies listed. For more go to http://www.thesubway.com.
All material herein was prepared by Capital Research Group, Inc. (CRG) based upon information believed to be reliable. The information contained herein is not guaranteed by CRG to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRG has been compensated by third party shareholders or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRG has been compensated forty thousand shares for RHGP. CRG has also purchased five thousand shares in the open market. CRG intends to sell its shares. CRG has sold approximately zero RHGP shares to date. CRG may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRG's affiliates, officers, directors and employees intend to buy and sell additional shares in any company mentioned within and may profit in the event those shares rise in value. CRG will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
Chuck Tamburello Phone: 954-217-8555 Fax: 954-217-1500
SOURCE: TheSUBWAY.com
Copyright 2007 Market Wire, All rights reserved.
Point Therapeutics vor der Wende?
Point Therapeutics liefert ein klinische Update am 01.03.07 zu den Zweiphasen3 Versuchen Stadium IIIB/IV im nicht-kleinen Zelle Lungenkrebs (NSCLC) und einen Phase 2 Versuch Stadium IV im pankreatischen Krebs mit einschließt!
Die bisherigen Resultate fielen sehr gemischt aus. Möglicher weise droht ein kompletter Ausfall einer Klinischen Studie.
Point Therapeutics besitze eine umfangreiche Pipeline die für eine Überraschung möglicher weise gut ist! Obwohl das Papier bisher nur eine Richtung kannte ist bei dem jetzigen Kurs mit einer technischen Erholung auf 2 Monate Sicht zu Rechnen.
Point Therapeutics liefert ein klinische Update am 01.03.07 zu den Zweiphasen3 Versuchen Stadium IIIB/IV im nicht-kleinen Zelle Lungenkrebs (NSCLC) und einen Phase 2 Versuch Stadium IV im pankreatischen Krebs mit einschließt!
Die bisherigen Resultate fielen sehr gemischt aus. Möglicher weise droht ein kompletter Ausfall einer Klinischen Studie.
Point Therapeutics besitze eine umfangreiche Pipeline die für eine Überraschung möglicher weise gut ist! Obwohl das Papier bisher nur eine Richtung kannte ist bei dem jetzigen Kurs mit einer technischen Erholung auf 2 Monate Sicht zu Rechnen.
Point-Therapeutik ist eine deutliche Bodenbildung erkennbar!
Technische Reaktion nach oben war in den vergangen Tagen zu beobachten. Diese wird in den nächsten Tagen an Geschwindigkeit zunehmen.
Dazu beitragen wird auch die diesjährige Jährliche Krebsforschung- Sitzung (AACR) in Los Angeles, Kalifornien, vom 14. bis 18. April 2007.
Sollten keine negativen Ergebnisse und Nachrichten nach gelegt werden sollte der Kurs die nächsten Woche weiter anziehen und diese zum Positionieren genutzt werden!
****************************************************************
Technische Reaktion nach oben war in den vergangen Tagen zu beobachten. Diese wird in den nächsten Tagen an Geschwindigkeit zunehmen.
Dazu beitragen wird auch die diesjährige Jährliche Krebsforschung- Sitzung (AACR) in Los Angeles, Kalifornien, vom 14. bis 18. April 2007.
Sollten keine negativen Ergebnisse und Nachrichten nach gelegt werden sollte der Kurs die nächsten Woche weiter anziehen und diese zum Positionieren genutzt werden!
****************************************************************
.14$
Antwort auf Beitrag Nr.: 29.404.148 von 50bager am 21.05.07 15:19:31kann mal bitte jmd. die aktuelle pipeline reinstellen und in welchen phasen sich die medis befinden wäre sehr nett
gruss
gruss
was meint ihr, gehts heute aufwärts in us??
Point Therapeutics Reduces Costs by Cutting Work Force
BOSTON, May 31, 2007 (BUSINESS WIRE) -- Point Therapeutics, Inc. (NASDAQ: POTP) today announced that to save costs it has reduced its workforce by approximately 60 percent. The Company estimates that the total charges for the workforce reduction will be approximately $130,000. This action follows the recent interim clinical results in which the Company's Independent Monitoring Committee recommended stopping the Company's two Phase 3 talabostat studies as a potential treatment for patients in advanced non-small cell lung cancer. As a result of the Company informing the U.S. Food and Drug Administration (FDA) of the interim results, the FDA has put the talabostat clinical program on hold.
The Company continues to assess its options given this recent data and will report on next steps once they have been decided.
Point Therapeutics Reduces Costs by Cutting Work Force
BOSTON, May 31, 2007 (BUSINESS WIRE) -- Point Therapeutics, Inc. (NASDAQ: POTP) today announced that to save costs it has reduced its workforce by approximately 60 percent. The Company estimates that the total charges for the workforce reduction will be approximately $130,000. This action follows the recent interim clinical results in which the Company's Independent Monitoring Committee recommended stopping the Company's two Phase 3 talabostat studies as a potential treatment for patients in advanced non-small cell lung cancer. As a result of the Company informing the U.S. Food and Drug Administration (FDA) of the interim results, the FDA has put the talabostat clinical program on hold.
The Company continues to assess its options given this recent data and will report on next steps once they have been decided.
hallo??
ist hier niemand mehr investiert?
Pipeline sieht doch vielversprechend aus??
ist hier niemand mehr investiert?
Pipeline sieht doch vielversprechend aus??
Antwort auf Beitrag Nr.: 29.577.480 von Ma0815sch am 01.06.07 17:25:11Höchste Vorsicht ist geboten!
Eine der Zweiphasen3 Studien ist gestoppt!
Die Firma wertet derzeit entsprechende Teststudien aus!
Talabostat ist in jeder dieser 2 & 3 Phasen Studien enthalten!
2 Phasen Studien sind in der Warte schleife da die Ergebnisse der letzten Zweiphasen3
Studie ausgewertet werden wobei hier nur Zwischenresultate vorliegen!
Die Firma muss diesen Jahr noch an
entsprechendes neues Kapital kommen !
Bei diesem Papier könnte es zu einem kompletten Kapitalverlust kommen.
Fazit: Derzeit meiden.....Entscheidung der FDA zur Weiterführung der Testreihe abwarten!
Eine der Zweiphasen3 Studien ist gestoppt!
Die Firma wertet derzeit entsprechende Teststudien aus!
Talabostat ist in jeder dieser 2 & 3 Phasen Studien enthalten!
2 Phasen Studien sind in der Warte schleife da die Ergebnisse der letzten Zweiphasen3
Studie ausgewertet werden wobei hier nur Zwischenresultate vorliegen!
Die Firma muss diesen Jahr noch an
entsprechendes neues Kapital kommen !
Bei diesem Papier könnte es zu einem kompletten Kapitalverlust kommen.
Fazit: Derzeit meiden.....Entscheidung der FDA zur Weiterführung der Testreihe abwarten!
Antwort auf Beitrag Nr.: 29.581.382 von Biotechspezialx am 01.06.07 21:19:23weiß man in welchen zeitraum die FDA eine entscheidung bekannt geben wird 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 207 | ||
| 119 | ||
| 59 | ||
| 50 | ||
| 46 | ||
| 39 | ||
| 38 | ||
| 30 | ||
| 30 | ||
| 28 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 15 | ||
| 14 | ||
| 14 |
